Company / SG&A Expense
Anixa Biosciences Inc SG&A Expense History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$7.4M
FY2024
5-year range
$5.7M / $7.4M
FY2020-FY2024
Trend
+3.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 3 consecutive years, from $6M in FY2020 to $7M in FY2024.
Based on SEC 10-K filings.
$7M in FY2024 with a 10-year CAGR of -0.7%.
Increased from $7M to $7M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +1.5%
- 10-Year CAGR
- -0.7%
Key checks
Key Insights
- Anixa Biosciences Inc's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +1.5%, indicating consistent growth.
- In FY2024, sg&a expense increased 3.7% year-over-year.
- Peak sg&a expense was recorded in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $7.4M | +3.7% |
| FY2023 | $7.2M | +1.4% |
| FY2022 | $7.1M | +24.9% |
| FY2020 | $5.7M | -18.1% |
| FY2019 | $6.9M | +56.7% |
| FY2018 | $4.4M | +62.8% |
| FY2017 | $2.7M | -50.9% |
| FY2016 | $5.5M | -14.0% |
| FY2015 | $6.4M | -19.8% |
| FY2014 | $8.0M | +178.1% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026